WOEST 2 | Dual Versus Triple Antithrombotic Scheme in the Real World.

The WOEST study found a significant reduction in bleeding complications post PCI with oral anticoagulation indication (OAC) when treating patients with dual antiplatelet therapy (DAPT) vs. the triple antithrombotic scheme. Several randomized studies have shown these results. At present, the guidelines recommend using the triple antithrombotic scheme in patients according to ischemic and bleeding risk. 

WOEST 2 | Uso de doble vs triple esquema antitrombótico en el mundo real

The WOEST 2 is a prospective multicenter registry aiming at assessing the use, efficacy, and safety of the combined use of OAC and antiplatelet antiaggregants after PCI in the real world.  

Safety primary end point was clinically relevant bleeding by BARC criteria. Efficacy primary end point was MACCE which included all cause death, AMI, stent thrombosis, ischemic stroke, and transient ischemic attack. Secondary end point included bleeding and ischemic events. 

1058 patients were included. Mean age was 74 and 24% were women. El 87% of patients were already on anticoagulants. The most frequently used were NOACS (53,1%), Rivaroxaban in particular. Clopidogrel was the most used antiplatelet. The most frequent presentation of patients undergoing PCI was ACS.  

At discharge, DAPT was indicated to 644 patients, while the remaining 414 were indicated the triple scheme. Patients receiving DAPT had more hypertension, prior stroke, stroke, cardiac failure and atrial fibrillation. 

Read also: Ticagrelor Shows Benefits in Coronary Microvascular Function after NSTEMI.

As regards the primary end point, the use of DAPT at discharge was associated with significant reduction of clinically relevant bleeding at one year vs. the use of the triple scheme (16.8% vs 23.6%; p=0.003). This difference was also observed when adjusting variables. However, there were no differences in major bleeding or hemorrhagic stroke.  

Looking at efficacy, researchers observed a higher rate of MACCE in the DAPT group at the expense of higher AMI rate, stent thrombosis and all cause death. However, this difference was not statistically relevant. 

Conclusion

In this prospective study of the real world, DAPT vs the triple antithrombotic scheme in patients with atrial fibrillation or mechanical valve prosthesis, showed lower risk of clinically relevant bleeding with no significant increase of ischemic events. 

Dr. Andrés Rodríguez
Member of the editorial board in SOLACI.org .

Original Title: Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study.

Reference: Willem Lambertus , MD et al EuroIntervention 2022;17.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...